Key result
This editorial summarizes a collection of articles highlighting the complex pathophysiology, novel biomarkers, and emerging therapeutic strategies for cardiometabolic HFpEF associated with type 2 diabetes.
This editorial introduces a special issue on cardiometabolic HFpEF, emphasizing the role of type 2 diabetes as a central pathogenic driver and highlighting the need for phenotype-driven, personalized management strategies.
The global burden of heart failure with preserved ejection fraction (HFpEF), particularly the cardiometabolic phenotype linked to type 2 diabetes mellitus (T2D), poses one of the most challenges in cardiovascular medicine. This phenotype arises from the concurrence of obesity, metabolic dysregulation, systemic inflammation, endothelial dysfunction, and myocardial fibrosis, thus creating a complex pathophysiological landscape with considerable clinical impact [ 1 ].
No takes yet. Share an insight, caveat, or question.
Gorica et al. (2025) conducted an editorial in Heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus. This editorial summarizes a collection of articles highlighting the complex pathophysiology, novel biomarkers, and emerging therapeutic strategies for cardiometabolic HFpEF associated with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: